Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab)

Canadian Journal of Ophthalmology

Volumn 45, Issue 1, 2010, Pages 36-40

  Ehmann, David ^a   García, Raúl ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Bevacizumab; Choroidal neovascularization; Dexamethasone; Verteporfin photodynamic therapy

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; VERTEPORFIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OPTICAL COHERENCE TOMOGRAPHY; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 76149131060     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i09-243     Document Type: Article

References (17)

1. Rosenfeld P, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
2. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993;115:786-91.
3. VEGF Inhibition Study in Ocular Neovascularization (VISION) Clinical Trial Group, D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular agerelated macular degeneration two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001.
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular agerelatedmacular degeneration.N Engl J Med 2004;351:2805-16.
5. Ahmadieh H, Taei R, Soheilian M, et al. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration. BMC Ophthalmology 2007;7:10.
6. Augustin A, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-40.
7. Navea A, Mataix J, Desco MC, Garcia-Pous M, Palacios E. One-year follow-up of combined customized therapy. Photo-dynamic therapy and bevacizumab for exudative age-related macular degeneration. Retina 2009;29:13-9.
8. Iranmanesh R, Eandi CM, Peiretti E, et al. The nature and frequency of neovascular age-related macular degeneration. Eur J Ophthalmol 2007;17:75-83.
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
10. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-90.
11. Bakri SJ, Couch SM, McCannel CA, Edwards AO. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration. Retina 2009;29:573-8.
12. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
13. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001;131:541-60.
14. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photo-dynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008;145: 862-74.
15. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003; 110:1517-25.
16. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
17. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.